Thomas Walter G, Brandenburger Yves, Autelitano Dominic J, Pham Thao, Qian Hongwei, Hannan Ross D
Molecular Endocrinology, Baker Medical Research Institute, Melbourne, Australia.
Circ Res. 2002 Feb 8;90(2):135-42. doi: 10.1161/hh0202.104109.
Angiotensin II (Ang II) may cause cardiac hypertrophy via type 1 Ang II receptors (AT(1)) on cardiomyocytes and through growth factors released from cardiac fibroblasts. Whereas cardiomyocyte-specific AT(1) receptor expression produces cardiac hypertrophy and remodeling in vivo, delineation of the signals that mediate growth to Ang II is challenging because the prevailing in vitro model (cultured neonatal cardiomyocytes) expresses low levels of AT(1) receptor and responds inconsistently to Ang II. In this study, when AT(1A) receptors were expressed using adenovirus in cultured neonatal cardiomyocytes, Ang II stimulated a robust hypertrophy that was not secondary to the release of cardiac fibroblast-derived factors, specifically endothelin-1. Hypertrophy was accompanied by the induction of the immediate-early response genes, c-fos and c-jun, and reexpression of atrial natriuretic peptide (ANP). Ang II-induced activation of an ANP promoter-reporter was inhibited by the dominant/negative mutants, GalphaqI and N17Ras, indicating that hypertrophic signaling by the AT(1A) receptor is via heterotrimeric G protein coupling and downstream Ras pathways. AT(1A)-mediated cardiomyocyte hypertrophy and mitogen-activated protein kinase (MAPK) activation were inhibited by the MAPK kinase inhibitor, PD98059, and the epidermal growth factor (EGF) receptor kinase antagonist, AG1478, but not by PKC inhibitor, bisindolylmaleimide-1. Moreover, Ang II-induced MAPK activation was prevented by treatment with a matrix metalloproteinase inhibitor, consistent with the tyrosine phosphorylation of the EGF receptor in response to AT(1A) receptor activation. These data unequivocally demonstrate that Ang II can directly promote cardiac myocyte growth via AT(1A) receptors expressed on these cells and reveal for the first time the important contribution of EGF receptor-transactivated MAPK signaling to this process.
血管紧张素 II(Ang II)可通过心肌细胞上的 1 型血管紧张素 II 受体(AT(1))以及心脏成纤维细胞释放的生长因子导致心肌肥大。虽然心肌细胞特异性 AT(1) 受体表达在体内会产生心肌肥大和重塑,但由于目前的体外模型(培养的新生心肌细胞)AT(1) 受体表达水平低且对 Ang II 反应不一致,因此确定介导对 Ang II 生长反应的信号具有挑战性。在本研究中,当使用腺病毒在培养的新生心肌细胞中表达 AT(1A) 受体时,Ang II 刺激了强烈的肥大反应,这并非继发于心脏成纤维细胞衍生因子(特别是内皮素 -1)的释放。肥大伴随着立即早期反应基因 c-fos 和 c-jun 的诱导以及心房利钠肽(ANP)的重新表达。Ang II 诱导的 ANP 启动子 - 报告基因的激活被显性/阴性突变体 GalphaqI 和 N17Ras 抑制,表明 AT(1A) 受体介导的肥大信号传导是通过异源三聚体 G 蛋白偶联和下游 Ras 途径。AT(1A) 介导的心肌细胞肥大和丝裂原活化蛋白激酶(MAPK)激活被 MAPK 激酶抑制剂 PD98059 和表皮生长因子(EGF)受体激酶拮抗剂 AG1478 抑制,但不受蛋白激酶 C 抑制剂双吲哚基马来酰亚胺 -1 抑制。此外,用基质金属蛋白酶抑制剂处理可阻止 Ang II 诱导的 MAPK 激活,这与 EGF 受体响应 AT(1A) 受体激活的酪氨酸磷酸化一致。这些数据明确表明,Ang II 可通过这些细胞上表达的 AT(1A) 受体直接促进心肌细胞生长,并首次揭示了 EGF 受体转活化的 MAPK 信号传导对这一过程的重要贡献。